Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 Inhibitors (Pembrolizumab, Nivolumab, Cemiplimab, & Others), Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022

Description

Immune checkpoint inhibitors are a part of immuno-oncology therapies, which involves use of patients' immune system to fight against cancer. Immuno-oncology uses novel immunotherapies such as immune checkpoint inhibitors that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immune checkpoint inhibitors are immunotherapy products that block the proteins, which stop immune system from attacking the cancer cells. These drugs block certain checkpoint proteins such as CTLA-4, PD-1, and PD-L1. Manufacturers are engaged in research and development of immune checkpoint inhibitors as standalone therapies as well as in combination with other immuno-oncology products. Immune checkpoint inhibitors work against a wide variety of cancer, which include non-small cell lung cancer, lymphoma, skin cancer, breast cancer, and others. Depending on the functioning of these therapies they are further classified into subtypes such as programmed death receptor-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic t-lymphocyte antigen 4 (CTLA-4) inhibitors. Commercially available immune checkpoint inhibitors include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

The rise in prevalence of cancer is expected to drive the global immune checkpoint inhibitors market. For instance, according to the American Cancer Society, in 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. In 2022, there will be approximately 4,820,000 and 2,370,000 new cancer cases, and 3,210,000 and 640,000 cancer deaths in China and the USA, respectively. Estimated numbers of new cancer cases and deaths in 2022 (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.)

Key features of the study:

This report provides an in-depth analysis of the global immune checkpoint inhibitors market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global immune checkpoint inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune checkpoint inhibitors market

Detailed Segmentation:

Global Immune Checkpoint Inhibitors Market, By Drug Class:
- Programmed Death Receptor-1 (PD-1) Inhibitors
  - Pembrolizumab (Keytruda)
  - Nivolumab (Opdivo)
  - Cemiplimab (Libtayo)
  - Others
- Programmed Death-Ligand 1 (PD-L1) Inhibitors
  - Atezolizumab (Tecentriq)
  - Avelumab (Bavencio)
  - Durvalumab (Imfinzi)
- CTL-4 Checkpoint Inhibitor
  - Ipilimumab (Yervoy)
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
Global Immune Checkpoint Inhibitors Market, By Cancer Type:
- Lung Cancer
- Head & Neck Cancer
- Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Blood Cancer (Lymphoma)
- Bladder Cancer (Urothelial Carcinoma)
- Renal/Kidney Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Immune Checkpoint Inhibitors Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Bristol-Myers Squibb Company*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
- Hoffmann-La Roche AG
- AstraZeneca Plc
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI2560

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Collaborations & Partnerships
Major FDA Approvals & Product Launch Scenario
Pipeline Analysis
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Programmed Death Receptor-1 (PD-1) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Pembrolizumab (Keytruda)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Nivolumab (Opdivo)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Cemiplimab (Libtayo)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Programmed Death-Ligand 1 (PD-L1) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Atezolizumab (Tecentriq)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Avelumab (Bavencio)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Durvalumab (Imfinzi)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
CTL-4 Checkpoint Inhibitor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Ipilimumab (Yervoy)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Lymphocyte-Activation Gene 3 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Immune Checkpoint Inhibitors Market, By Cancer Type, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Head & Neck Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Skin Cancer (Melanoma and Merkel Cell Carcinoma)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Blood Cancer (Lymphoma)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Bladder Cancer (Urothelial Carcinoma)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Renal/Kidney Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Colorectal Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Immune Checkpoint Inhibitors Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profiles
- Bristol-Myers Squibb Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Merck & Co., Inc.
- F. Hoffmann-La Roche AG
- AstraZeneca Plc
- Novartis International AG
- ImmunOs Therapeutics AG
- Immutep Ltd.
- NewLink Genetics Corporation
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.

10. Section

References
Research Methodology
About Us and Sales Contact

Immune Checkpoint Inhibitors Market, by Drug Class (Programmed Death Receptor-1 Inhibitors (Pembrolizumab, Nivolumab, Cemiplimab, & Others), Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030